Jeff Jones
Stock Analyst at Oppenheimer
(3.67)
# 745
Out of 4,413 analysts
50
Total ratings
29.55%
Success rate
14.79%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Initiates: Outperform | $53 | $33.62 | +57.64% | 1 | Apr 22, 2024 | |
| ZURA Zura Bio | Reiterates: Outperform | $17 → $16 | $4.27 | +274.71% | 1 | Apr 1, 2024 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $1.2 → $1.5 | $1.68 | -10.71% | 3 | Apr 1, 2024 | |
| ANTX AN2 Therapeutics | Reiterates: Perform | n/a | $2.40 | - | 3 | Apr 1, 2024 | |
| CLRB Cellectar Biosciences | Reiterates: Outperform | $11 → $12 | $3.09 | +288.35% | 2 | Mar 28, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $8 → $7 | $1.55 | +351.61% | 1 | Mar 20, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterates: Outperform | $51 → $58 | $37.04 | +56.59% | 4 | Mar 13, 2024 | |
| VTYX Ventyx Biosciences | Upgrades: Outperform | $12 | $3.74 | +220.86% | 8 | Mar 12, 2024 | |
| CMMB Chemomab Therapeutics | Maintains: Perform | n/a | $0.70 | - | 5 | Mar 8, 2024 | |
| MCRB Seres Therapeutics | Maintains: Outperform | $9 → $5 | $0.99 | +404.74% | 2 | Mar 6, 2024 | |
| EVH Evolent Health | Initiates: Outperform | $45 | $27.74 | +62.22% | 1 | Mar 1, 2024 | |
| FUSN Fusion Pharmaceuticals | Maintains: Outperform | $13 → $15 | $21.43 | -30.00% | 3 | Jan 5, 2024 | |
| PLRX Pliant Therapeutics | Maintains: Outperform | $51 → $52 | $11.82 | +339.93% | 4 | Aug 10, 2023 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Outperform | $120 | $2.12 | +5,560.38% | 3 | May 25, 2023 | |
| PMVP PMV Pharmaceuticals | Reiterates: Outperform | $15 | $1.80 | +733.33% | 5 | May 11, 2023 | |
| MBRX Moleculin Biotech | Reiterates: Outperform | $75 | $5.02 | +1,394.02% | 2 | Mar 24, 2023 | |
| EVAX Evaxion Biotech | Maintains: Outperform | $160 → $110 | $4.17 | +2,537.89% | 2 | Nov 17, 2022 |
Kymera Therapeutics
Apr 22, 2024
Initiates: Outperform
Price Target: $53
Current: $33.62
Upside: +57.64%
Zura Bio
Apr 1, 2024
Reiterates: Outperform
Price Target: $17 → $16
Current: $4.27
Upside: +274.71%
Perspective Therapeutics
Apr 1, 2024
Reiterates: Outperform
Price Target: $1.2 → $1.5
Current: $1.68
Upside: -10.71%
AN2 Therapeutics
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $2.40
Upside: -
Cellectar Biosciences
Mar 28, 2024
Reiterates: Outperform
Price Target: $11 → $12
Current: $3.09
Upside: +288.35%
Corvus Pharmaceuticals
Mar 20, 2024
Maintains: Outperform
Price Target: $8 → $7
Current: $1.55
Upside: +351.61%
Corbus Pharmaceuticals Holdings
Mar 13, 2024
Reiterates: Outperform
Price Target: $51 → $58
Current: $37.04
Upside: +56.59%
Ventyx Biosciences
Mar 12, 2024
Upgrades: Outperform
Price Target: $12
Current: $3.74
Upside: +220.86%
Chemomab Therapeutics
Mar 8, 2024
Maintains: Perform
Price Target: n/a
Current: $0.70
Upside: -
Seres Therapeutics
Mar 6, 2024
Maintains: Outperform
Price Target: $9 → $5
Current: $0.99
Upside: +404.74%
Evolent Health
Mar 1, 2024
Initiates: Outperform
Price Target: $45
Current: $27.74
Upside: +62.22%
Fusion Pharmaceuticals
Jan 5, 2024
Maintains: Outperform
Price Target: $13 → $15
Current: $21.43
Upside: -30.00%
Pliant Therapeutics
Aug 10, 2023
Maintains: Outperform
Price Target: $51 → $52
Current: $11.82
Upside: +339.93%
Cyclacel Pharmaceuticals
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $2.12
Upside: +5,560.38%
PMV Pharmaceuticals
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.80
Upside: +733.33%
Moleculin Biotech
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $5.02
Upside: +1,394.02%
Evaxion Biotech
Nov 17, 2022
Maintains: Outperform
Price Target: $160 → $110
Current: $4.17
Upside: +2,537.89%